AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day.
Top Analyst Reports for Johnson & Johnson, NVIDIA & Cisco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NVIDIA Corporation (NVDA) and Cisco Systems, Inc. (CSCO).
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
by Zacks Equity Research
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
by Zacks Equity Research
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $102.80 in the latest trading session, marking a -0.88% move from the prior day.
3 Stocks with Strong Dividends to Buy for Growth in 2021
by Benjamin Rains
Investors might want to consider adding stocks to their 2021 portfolios that pay a solid dividend and provide exposure to growth areas...
Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
by Zacks Equity Research
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $104.64, marking a +1.77% move from the previous day.
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
by Zacks Equity Research
Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion
by Zacks Equity Research
AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.
3 Large-Cap Dividend Stocks to Buy and Hold Before 2021
by Benjamin Rains
Investors might not want to jump into stocks that are banking on a highly successful vaccine rollout. Therefore, we focused on 3 large-cap giants from completely different industries that pay a dividend and look poised to grow no matter what happens...
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
by Zacks Equity Research
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.
Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.
The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.
Top Stock Reports for Facebook, Netflix & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).
3 Top Lessons Learned from Buffett's 2020 Portfolio Moves
by Tracey Ryniec
During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?
Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie
by Zacks Equity Research
Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie
AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.